Advertisement

Chinese Science Bulletin

, Volume 47, Issue 19, pp 1650–1653 | Cite as

Specific myeloprotection via multidrug resistance 1 gene controlled by aminopeptidase N myeloid promoter

  • Libo Liang
  • Yewei Ma
  • Xiaoshan Zhou
  • Jun Yang
  • Yanchun Li
  • Yuying Liu
  • Zheng Wang
  • Qingzheng Zhao
Notes

Abstract

In the treatment of tumor patients introduction of multidrug resistance genes into hematopoietic cells has been reported as an approach for reducing myelotoxicity created by antitumor drugs. However, the nonspecific expression of the genes can also increase the chemoresistance of the tumor cells invaded into bone marrow, which influences seriously the effectiveness of chemotherapy. In this study, a new strategy is described for specific myeloprotection. The recombinant retroviral vector containing multidrug resistance 1 (MDR1) gene regulated by aminopeptidase N (APN) myeloid promoter was constructed and then introduced into myeloblastic cells KG1a and tumor cell line BEL7402. The specific transcript ofMDR1 was detected in KG1a cells transduced withMDR1 gene and rhodamine 123 was effectively extruded by Pgp, the protein ofMDR1 gene. The resistance elevated markedly by 10.6, 10.4, 11.2, 4.2 and 14.2 folds inMDR1 gene-transduced KG1a cells to chemotherapeutic drugs such as cochicine, VP-16, vincristine, doxorubicin and paclitaxel, respectively. In contrast, the chemoresistance had no significant changes in BEL7402 cells transduced withMDR1 gene. Expression ofMDR1 directed byAPN myeloid promoter resulted in myelospecific protection during the killing of tumor cells treated with antitumor drugs. The study would provide a new mean for circumventing myelosuppression of tumor patients undergoing chemotherapy.

Keywords

animopeptidase N myelo-specific promoter MDR1 retroviral vector hepatoma cell myeloid cell 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Sorrentino, B. P., McDonagh, K. T., Woods, D. et al., Expression of retroviral vectors containing the human multidrug resistance 1 cDNA in hematopoietic cells of transplanted mice, Blood, 1995, 86: 491.Google Scholar
  2. 2.
    Ward, M., Richardson, C., Pioli, P. et al., Transfer and expression of the human multiple drug resistance gene in human CD34+ cells, Blood, 1994, 84: 1408.Google Scholar
  3. 3.
    Yang, J., Wu, Y., Ma, P. et al., Construction and expression of retroviruses encoding dual drug resistance genes in human umbilical cord blood CD34+ cells, Chinese Science Bulletin, 2000, 45(15): 1390.CrossRefGoogle Scholar
  4. 4.
    Liang, L. B., Ma, Y. W., Zhao, Q. Z. et al., Cloning of aminopeptidase N promoter and its activity in hematopoietic cell and different tumor cell lines, Chinese Science Bulletin, 2001, 46(19): 1649.CrossRefGoogle Scholar
  5. 5.
    Gazit, G., Kane, S. E., Nichols, P. et al., Use of the stress-inducible grp78/BiP promoter in targeting high level gene expression in fibrocomain vivo, Cancer Res., 1995, 55: 1660.Google Scholar
  6. 6.
    Yang, J. M., Goldenberg, S., Gottesman, M. M. et al., Characteristics of P388/VMDRC04, a simple sensitive model for studying P-glycoprotein antagonists, Cancer Res., 1994, 54: 730.Google Scholar
  7. 7.
    Sikora, K., Gene therapy for cancer, Trends. Biotech., 1993, 11: 197.CrossRefGoogle Scholar
  8. 8.
    Miller, N., Vile, R. G., Targeted vectors for gene therapy, FASEB. J., 1995, 9: 190.Google Scholar
  9. 9.
    Miller, N., Whelan, J., Progessionin transcriptionally targeted and regulated vectors for genetic therapy, Hum. Gene. Ther., 1997, 8: 803.CrossRefGoogle Scholar
  10. 10.
    Tong, Y., Pang, L. Y., Zhou, S. et al., Protection of hematopoietic cells transduced with multidrug resistance 1 gene, Chin. J. Onco. (in Chinese), 2000, 22: 214.Google Scholar
  11. 11.
    Deisseroth, A. B., Holmes, F., Hortobagyi, G. et al., Use of safety-modified retrovirus to introduce chemotherapy resistance sequences into normal hematopoietic cells for chemoprotection during the therapy of breast cancer: a pilot trial, Hum. Gene. Ther., 1996, 7: 401.CrossRefGoogle Scholar
  12. 12.
    Kavanagh, J., Hanania, E., Giles, R. et al., Genetic modification of cells used for transplant following intensive therapy for ovarian cancer and breast cancer, Blood, 1996, 88(Suppl. 1): 272a.Google Scholar

Copyright information

© Science in China Press 2002

Authors and Affiliations

  • Libo Liang
    • 1
  • Yewei Ma
    • 1
  • Xiaoshan Zhou
    • 1
  • Jun Yang
    • 2
  • Yanchun Li
    • 1
  • Yuying Liu
    • 1
  • Zheng Wang
    • 1
  • Qingzheng Zhao
    • 1
  1. 1.Cancer InstitutePeking Union Medical College and Chinese Academy of Medical SciencesBeiingChina
  2. 2.Institute of Blood Transfusion MedicineBeijingChina

Personalised recommendations